Tri M. Pham

Tri M. Pham

Auto-generated profile, based on publicly available information

Tri M. Pham

Department of Pathology, Barbara Ann Karmanos Institute, Wayne State University School of Medicine, Detroit, Michigan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2024 in Cancer Research
Verified
Journal Article
Open access
TBTae Hyun Bae
Tae Hyun Bae
KSKi Woon Sung
Ki Woon Sung
TPTri M. Pham
Tri M. Pham
ANAbdo J. Najy
Abdo J. Najy
AZAlaleh Zamiri
Alaleh Zamiri
Hyeong-Reh KimHyeong-Reh Kim
Hyeong-Reh Kim
Genetic alterations play a pivotal role in various human diseases, particularly cancer. The androgen receptor (AR) is a crucial transcription factor driving prostate cancer progression across all stages. Current AR-targeting therapies utilize competitive AR antagonists or pathway suppressors. However, therapy resistance often emerges due to AR mutations and AR splice variants, such as AR-v7. To overcome this, we developed ATC-324, an AR degrader using the innovative protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 was designed to comprise enzalutamide, an AR inhibitor, as a target-binding ligand and YT 6-2, a ligand of the autophagy receptor p62/SQSTM1, as an autophagy-targeting ligand. ATC-324 induces the formation of the AR/p62 complex, leading to autophagy–lysosomal degradation of AR. Importantly, ATC-324 effectively degrades AR mutants frequently detected in prostate cancer and codegrades AR-v7 as a heterodimer with full-length AR. ATC-324 reduces nuclear AR levels and downregulates the target gene expression of AR and AR-v7, leading to cytotoxicity in AR-positive prostate cancer cells. We also provide evidence of the therapeutic potential of ATC-324 in vivo as well as ex vivo bone organ culture. Moreover, ATC-324 remains potent in enzalutamide-resistant prostate cancer cells. These results demonstrate the potential of the AUTOTAC platform to target previously considered undruggable proteins and overcome certain drug resistance mechanisms. Significance: The characterization of an AUTOTAC-based degrader capable of inducing autophagic degradation of wild-type and mutated androgen receptors demonstrates the potential of this approach for targeting castration-resistant prostate cancer and overcoming drug resistance.

15 January 2025
Verified
Other
Open access
PDF file
TBTae Hyun Bae
Tae Hyun Bae
KSKi Woon Sung
Ki Woon Sung
TPTri M. Pham
Tri M. Pham
ANAbdo J. Najy
Abdo J. Najy
AZAlaleh Zamiri
Alaleh Zamiri
Hyeong-Reh KimHyeong-Reh Kim
Hyeong-Reh Kim
Supplementary legends Supplementary Tables 1-3 Supplementary Figures 1-8

17 June 2026
Verified
Other
Open access
PDF file
TBTae Hyun Bae
Tae Hyun Bae
KSKi Woon Sung
Ki Woon Sung
TPTri M. Pham
Tri M. Pham
ANAbdo J. Najy
Abdo J. Najy
AZAlaleh Zamiri
Alaleh Zamiri
Hyeong-Reh KimHyeong-Reh Kim
Hyeong-Reh Kim
Supplementary legends Supplementary Tables 1-3 Supplementary Figures 1-8

17 June 2026
Verified
Other
Open access
TBTae Hyun Bae
Tae Hyun Bae
KSKi Woon Sung
Ki Woon Sung
TPTri M. Pham
Tri M. Pham
ANAbdo J. Najy
Abdo J. Najy
AZAlaleh Zamiri
Alaleh Zamiri
Hyeong-Reh KimHyeong-Reh Kim
Hyeong-Reh Kim
Genetic alterations play a pivotal role in various human diseases, particularly cancer. The androgen receptor (AR) is a crucial transcription factor driving prostate cancer progression across all stages. Current AR-targeting therapies utilize competitive AR antagonists or pathway suppressors. However, therapy resistance often emerges due to AR mutations and AR splice variants, such as AR-v7. To overcome this, we developed ATC-324, an AR degrader using the innovative protein degradation technology platform AUTOphagy-TArgeting Chimera (AUTOTAC). ATC-324 was designed to comprise enzalutamide, an AR inhibitor, as a target-binding ligand and YT 6-2, a ligand of the autophagy receptor p62/SQSTM1, as an autophagy-targeting ligand. ATC-324 induces the formation of the AR/p62 complex, leading to autophagy–lysosomal degradation of AR. Importantly, ATC-324 effectively degrades AR mutants frequently detected in prostate cancer and codegrades AR-v7 as a heterodimer with full-length AR. ATC-324 reduces nuclear AR levels and downregulates the target gene expression of AR and AR-v7, leading to cytotoxicity in AR-positive prostate cancer cells. We also provide evidence of the therapeutic potential of ATC-324 in vivo as well as ex vivo bone organ culture. Moreover, ATC-324 remains potent in enzalutamide-resistant prostate cancer cells. These results demonstrate the potential of the AUTOTAC platform to target previously considered undruggable proteins and overcome certain drug resistance mechanisms.Significance:The characterization of an AUTOTAC-based degrader capable of inducing autophagic degradation of wild-type and mutated androgen receptors demonstrates the potential of this approach for targeting castration-resistant prostate cancer and overcoming drug resistance.